WO2008088548A3 - Disintegrin variants and pharmaceutical uses thereof - Google Patents

Disintegrin variants and pharmaceutical uses thereof Download PDF

Info

Publication number
WO2008088548A3
WO2008088548A3 PCT/US2007/026125 US2007026125W WO2008088548A3 WO 2008088548 A3 WO2008088548 A3 WO 2008088548A3 US 2007026125 W US2007026125 W US 2007026125W WO 2008088548 A3 WO2008088548 A3 WO 2008088548A3
Authority
WO
WIPO (PCT)
Prior art keywords
disintegrin
integrin
angiogenesis
variant
retinopathy
Prior art date
Application number
PCT/US2007/026125
Other languages
French (fr)
Other versions
WO2008088548A2 (en
Inventor
Woei-Jer Chuang
Wen-Mei Fu
Tur-Fu Huang
Wenya Huang
Chih-Hsin Tang
Chiu-Yueh Chen
Original Assignee
Univ Nat Taiwan
Dcb Usa Llc
Woei-Jer Chuang
Wen-Mei Fu
Tur-Fu Huang
Wenya Huang
Chih-Hsin Tang
Chiu-Yueh Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ577998A priority Critical patent/NZ577998A/en
Priority to JP2009544049A priority patent/JP5908666B2/en
Priority to BRPI0720636-4A priority patent/BRPI0720636A2/en
Priority to RU2009128647/10A priority patent/RU2477727C2/en
Application filed by Univ Nat Taiwan, Dcb Usa Llc, Woei-Jer Chuang, Wen-Mei Fu, Tur-Fu Huang, Wenya Huang, Chih-Hsin Tang, Chiu-Yueh Chen filed Critical Univ Nat Taiwan
Priority to AU2007343734A priority patent/AU2007343734B2/en
Priority to KR1020097015644A priority patent/KR20090108049A/en
Priority to CA002672091A priority patent/CA2672091A1/en
Priority to CN200780051774.5A priority patent/CN101677537B/en
Priority to MX2009007065A priority patent/MX2009007065A/en
Priority to EP07867921A priority patent/EP2124548B1/en
Priority to ES07867921T priority patent/ES2389697T3/en
Publication of WO2008088548A2 publication Critical patent/WO2008088548A2/en
Publication of WO2008088548A3 publication Critical patent/WO2008088548A3/en
Priority to IL199564A priority patent/IL199564A/en
Priority to HK10103274.9A priority patent/HK1136160A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin avß3 receptor-antagonist activity and substantially reduced integrin aIIbß3 and/or a5ß1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin aIIbß3 and/or a5ß1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of avß3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.
PCT/US2007/026125 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof WO2008088548A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020097015644A KR20090108049A (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof
BRPI0720636-4A BRPI0720636A2 (en) 2006-12-26 2007-12-21 METHODS FOR TREATMENT AND / OR PREVENTION OF A DISEASE AND CHANGE, METHOD FOR INHIBITING AND / OR PREVENTING BONE TUMOR CELL GROWTH AND SYMPTOMS RELATED TO INBECYPLE, ANBYTIC, PHYSICAL, COMPLEXY, ANBYTIC, COMPOSITIVE, POLYPEETIC, COMPLEXY, POLYPETITIS , METHOD FOR PREPARING A POLYPEPTIDE, AND POLYNUCLEOTIDE
RU2009128647/10A RU2477727C2 (en) 2006-12-26 2007-12-21 αvβ3 SELECTIVE POLYPEPTIDE, METHOD FOR PREPARING IT, POLYNUCLEOTIDE CODING IT, COMPOSITION CONTAINING SAID PEPTIDE, AND METHOD FOR TREATING AND PREVENTING
CN200780051774.5A CN101677537B (en) 2006-12-26 2007-12-21 Disintegrin variant and pharmaceutical use thereof
AU2007343734A AU2007343734B2 (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof
JP2009544049A JP5908666B2 (en) 2006-12-26 2007-12-21 Disintegrin variants and their pharmaceutical use
CA002672091A CA2672091A1 (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof
NZ577998A NZ577998A (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof
MX2009007065A MX2009007065A (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof.
EP07867921A EP2124548B1 (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof
ES07867921T ES2389697T3 (en) 2006-12-26 2007-12-21 Variants of disintegration and pharmaceutical uses thereof
IL199564A IL199564A (en) 2006-12-26 2009-06-25 Isolated polypeptide selective for αvβ3 integrin, physiologically acceptable composition comprising same, method of making and uses thereof
HK10103274.9A HK1136160A1 (en) 2006-12-26 2010-03-30 Disintegrin variants and pharmaceutical uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87185406P 2006-12-26 2006-12-26
US60/871,854 2006-12-26

Publications (2)

Publication Number Publication Date
WO2008088548A2 WO2008088548A2 (en) 2008-07-24
WO2008088548A3 true WO2008088548A3 (en) 2008-10-16

Family

ID=39636522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/026125 WO2008088548A2 (en) 2006-12-26 2007-12-21 Disintegrin variants and pharmaceutical uses thereof

Country Status (16)

Country Link
US (1) US7943728B2 (en)
EP (2) EP2124548B1 (en)
JP (3) JP5908666B2 (en)
KR (1) KR20090108049A (en)
CN (1) CN101677537B (en)
AU (1) AU2007343734B2 (en)
BR (1) BRPI0720636A2 (en)
CA (1) CA2672091A1 (en)
ES (1) ES2389697T3 (en)
HK (1) HK1136160A1 (en)
IL (1) IL199564A (en)
MX (1) MX2009007065A (en)
NZ (2) NZ598176A (en)
RU (2) RU2477727C2 (en)
TW (1) TWI392738B (en)
WO (1) WO2008088548A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
CN101481412B (en) * 2009-02-09 2011-08-10 吉林大学 Polypeptide with antineoplastic function, encoding gene and use thereof
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung Polypeptides selective for av 3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof
WO2011062786A2 (en) * 2009-11-06 2011-05-26 Virginia Tech Intellectual Properties, Inc. Compounds and methods for inhibiting the metastasis of cancer cells
WO2011079175A1 (en) * 2009-12-23 2011-06-30 National Cheng Kung University Compositions and methods for the treatment of angiogenesis-related eye diseases
CN103327996B (en) * 2010-11-01 2016-06-15 延世大学校产学协力团 Thrombolysis composition and comprise its angiostenosis or the medicine for treatment agent composition of occlusive disease
EP3029071B1 (en) 2013-07-30 2018-07-11 Industry-Academic Cooperation Foundation, Yonsei University Saxatilin-fc fusion protein and use thereof
WO2015147616A1 (en) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Composition for preventing, inhibiting, or treating neuritis, containing peptide or protein including rgd motif
EP3182988A4 (en) * 2014-08-22 2018-05-23 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
CN107206047B (en) 2014-12-31 2021-07-23 汇恩斯株式会社 Composition comprising peptides containing the RGD motif or fragments thereof for treating burns and glaucoma, reducing skin wrinkles and promoting hair growth
CN104774247B (en) * 2015-04-20 2018-06-05 中国药科大学 With 3 relevant 5 peptides of integrin receptor α v β
AU2016286432B2 (en) * 2015-06-28 2019-02-14 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
WO2018048477A1 (en) * 2016-09-06 2018-03-15 Debina Diagnostics, Inc. Engineering and utility of fluorescent nanodiamond particles (ndp-f) for diagnostics and treatment of blood clots in human and veterinary medicine
WO2018048887A1 (en) 2016-09-06 2018-03-15 Debina Diagnostics, Inc. Nanodiamond particles and related devices and methods
US11202854B2 (en) * 2017-08-09 2021-12-21 National Taiwan University Disintegrin variants and uses thereof
EP3987313A4 (en) * 2019-06-18 2023-10-18 Debina Diagnostics, Inc. Compositions and articles comprising (nano)diamond particles
BR102021016135A2 (en) * 2021-08-16 2023-02-23 Novageia Biotecnologia Ltda MACROCYCLIC MIMETIC ANTAGONISTS WITH BIOLOGICAL ACTIVITY, THEIR USES AND COMPOSITIONS
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) * 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) * 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0382451A3 (en) * 1989-02-07 1991-05-29 Merck & Co. Inc. Viper venom polypeptides and variants
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
JPH05255395A (en) * 1990-10-26 1993-10-05 Takeda Chem Ind Ltd Polypeptide and its production
US5380646A (en) * 1992-10-19 1995-01-10 Temple University Of The Commonwealth System Of Higher Education Thrombus detection using radiolabelled disintegrins
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
JP4039856B2 (en) * 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Integrin expression inhibitor
AU2003248633A1 (en) * 2002-06-07 2003-12-22 Wisconsin Alumni Research Foundation Chemical synthesis of reagents for peptide coupling
US7271245B2 (en) * 2004-02-13 2007-09-18 The Scripps Research Institute Methods and compositions for inhibition of metastasis
AU2006336468B2 (en) * 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YANG, R-S.: "Rhodostomin inhibits thrombin-enhanced adhesion of ROS 17/2.8 cells through the blockade of avb3 integrin", TOXICON, vol. 46, no. 4, 26 July 2005 (2005-07-26), pages 387 - 393, XP005045655 *

Also Published As

Publication number Publication date
NZ577998A (en) 2012-03-30
EP2124548B1 (en) 2012-06-13
CN101677537B (en) 2016-08-17
ES2389697T3 (en) 2012-10-30
CN101677537A (en) 2010-03-24
RU2477727C2 (en) 2013-03-20
JP2016047818A (en) 2016-04-07
AU2007343734A2 (en) 2009-09-03
EP2522676A3 (en) 2013-02-27
JP2013151502A (en) 2013-08-08
IL199564A (en) 2015-05-31
BRPI0720636A2 (en) 2014-01-07
AU2007343734B2 (en) 2014-01-30
WO2008088548A2 (en) 2008-07-24
TWI392738B (en) 2013-04-11
JP5908666B2 (en) 2016-04-26
US7943728B2 (en) 2011-05-17
US20080188413A1 (en) 2008-08-07
RU2009128647A (en) 2011-02-10
JP2010514444A (en) 2010-05-06
EP2124548A4 (en) 2010-05-05
HK1136160A1 (en) 2010-06-25
EP2522676A2 (en) 2012-11-14
RU2012148887A (en) 2014-05-27
AU2007343734A1 (en) 2008-07-24
CA2672091A1 (en) 2008-07-24
NZ598176A (en) 2013-08-30
TW200848070A (en) 2008-12-16
KR20090108049A (en) 2009-10-14
MX2009007065A (en) 2009-10-13
EP2124548A2 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
WO2008088548A3 (en) Disintegrin variants and pharmaceutical uses thereof
NZ586003A (en) Antigen binding proteins that bind beta-amyloid peptide
WO2003104270A3 (en) Dudulin genes, non-human animal model: uses in human hematological disease
MX2009003729A (en) Rna antagonist compounds for the modulation of pcsk9.
MX351414B (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
MX2010003774A (en) Aqueous ophthalmic formulations.
BRPI0519508A2 (en) aminopyrazine analogues for the treatment of glaucoma and other rho kinase-mediated diseases or conditions
WO2009045370A3 (en) Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
BR112014007675A2 (en) degenerative joint disease treatment
DE60141409D1 (en) HOMOLOGO OF NOGO RECEPTOR
ATE522215T1 (en) USE OF 3,11B-CIS-DIHYDROTETRABENAZINE TO TREAT SYMPTOMS OF HUNTINGTON CHOREA
WO2014111458A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
WO2009015840A2 (en) Polypeptide for targeting of neural cells
WO2007126364A8 (en) Use of antisecretory factors for treating intraocular hypertension
WO2010079978A3 (en) Composition for improving inflammatory disease using abh antigens
EA200901067A1 (en) USE OF SEMAFORIN 6A AS A MIELINIZATION PROMOTER AND DIFFERENTIATION OF OLIGODENDROCYTES
BR112015003947A2 (en) fusion proteins and methods for treating, preventing or ameliorating pain
NZ596434A (en) Protein product and process for making injectable protein product
WO2012075173A3 (en) Compositions and method for deimmunization of proteins
WO2007149594A3 (en) Modified ribonucleases
TW200735888A (en) Treatment of epstein-barr virus-associated diseases
WO2007025229A3 (en) Compositions and their uses directed to hsp27
WO2006127913A3 (en) Modulation of lmw-ptpase expression
WO2007109174A3 (en) Compositions and methods for modulation of mcl-1 expression
MX350145B (en) Proteolytic extract from bromelain for the treatment of connective tissue disorders.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780051774.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07867921

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2672091

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009544049

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 577998

Country of ref document: NZ

Ref document number: 2007343734

Country of ref document: AU

Ref document number: MX/A/2009/007065

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2498/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007867921

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007343734

Country of ref document: AU

Date of ref document: 20071221

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097015644

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009128647

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0720636

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090625